Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2004-002353-31-DK
EUCTR2004-002353-31-DK
Active, not recruiting
Phase 1

A fase I/II trial with docetaxel and gemcitabine in hormone refractory prostate cancer

Organisation name was not entered0 sites60 target enrollmentJuly 9, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHormone fractory prostate cancer

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hormone fractory prostate cancer
Sponsor
Organisation name was not entered
Enrollment
60
Status
Active, not recruiting
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 9, 2008
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
Organisation name was not entered

Eligibility Criteria

Inclusion Criteria

  • •Histological documented prostate carcinoma
  • •Hormonrefractary disease
  • •Metastatic disease
  • •PSA\>10 microg/l
  • •Progressive rise in PSA in two measurement (\>25%)
  • •Castrate level of testosterone
  • •Performance status \<\=2
  • •No prior treatment with estrogens or prednisolon for prostate cancer
  • •No radionucleid treatment
  • •No concurrent bisphosphonates

Exclusion Criteria

  • •Radiotherapy involving more than 25% of bonemarrow area
  • •Other or prior malignant disease except squamous cell skin cancer.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Phase II study with gemcitabine/docetaxel first line in women with metastatic breast cancer - SF- 2Gem/taxoncological patients onlyMedDRA version: 6.1Level: PTClassification code 10055113
EUCTR2005-006168-71-ITA.S.L. 270
Recruiting
Phase 2
Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomasadvanced bone and soft tissue sarcomas
JPRN-UMIN000031004Kobe University20
Recruiting
Phase 2
GD therapy for advanced sarcomasadvanced pretreated bone and soft tissue sarcomas
JPRN-jRCTs051180042Hara Hitomi20
Active, not recruiting
Not Applicable
Phase II study with gemcitabine/docetaxel fist line in women with metastatic breast cancer. - SF2gem/taxOncologic patients only.MedDRA version: 6.1Level: PTClassification code 10055113
EUCTR2006-000165-10-ITA.S.L. 2 SAVONA70
Recruiting
Phase 2
Study of gemcitabine docetaxel in synovial sarcoma in relapsed metastatic setting
CTRI/2020/02/023612Department of Medical Oncology